Ensysce Biosciences Inc (ENSC)

[Shift-4]

The implications of this stock are ridiculous fundamentally speaking, but what has me intrigued is the expiration of the financing restrictions established by GEM Bahamas as a condition of Ensysce's RM with (formerly) LACQ.

The three-year terms of the financing restrictions were established in late December of 2020, but their effective date was July, 2021. It established a revolving line-of-credit with GEM, whereby the company could access up to $60M of capital by issuing shares at 90% of a preceding interval price to GEM Bahamas. This gives GEM a vested interest in shorting the stock relentlessly to ensure that any conversion would result in maximum share allocation (to them) and maximum dilution (to shareholders). The embedded restrictions severely hampered ENSC's ability to secure alternative financing.

The company has run a razor-lean operation to avoid tapping this line of credit, and has been unable to consider other financing offers while the contract is in effect. GEM has rather obviously been running a ruthless naked shorting operation to ensure that any redemption earns them maximum future profit. The July expiration of this arrangement means no more need for either, and I expected the market rebound to begin in anticipation of this. It appears to have begun; I believe it will continue. And I think the company is going to have a lot to reveal to shareholders about what they've been arranging for when the financial handcuffs come off.

There are a large number of significant developments this company could announce which would positively impact the share price. But this key issue is, I believe, the explanation for both the historic devaluation of the stock to truly absurd levels, and also why no previous runs have been sustainable. Its ending marks a new beginning for ENSC, and in my opinion an historic run when the market re-adjusts.

-$